Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
Holding ONC?
Track your performance easily
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$126.97 - $248.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)377.42K
Market Cap
$24.39B
Enterprise Value$22.17B
Total Cash (Recent Filing)$100.49M
Total Debt (Recent Filing)$6.19M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 26, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.24
Shares Outstanding97,717,560
10 Day Avg. Volume404,612
30 Day Avg. Volume377,417
Standard Deviation0.13
R-Squared0.06
Alpha0.00304
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.48
Price to Cash Flow (P/CF)28.50
P/FCF Ratio74.30
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue6.68
Enterprise Value/Gross Profit10.66
Enterprise Value/Ebitda-29.61
Forecast
1Y Price Target
$258.65Price Target Upside14.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Business StrategyONC opened the first US manufacturing facility in NJ, enhancing efficient tech transfer and shared global resources.
Financial PerformanceONC stock had +22% price appreciation entering 2025, reflecting investors' confidence in the long-term outlook.
Market PositionGlobal sales of zanubrutinib reached US$690mn in 3Q24, with its share in the global BTKi market increasing to ~25%, indicating strong market performance.
Bears Say
Growth RateThe approximately 8% quarter-on-quarter growth rate is lower than prior quarters, where growth has been typically in the mid-to-high teens.
Market CompetitionThe company faces fierce competition in the BTK inhibitor market in China.
Sales PerformanceThe sales of the self-developed drug pamiparib decreased by 48.3% year-on-year.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ONC FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $248.16 in the past 12 months.
What is BeiGene’s market cap?
BeiGene’s market cap is $24.39B.
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Mar 26, 2025 which is in 53 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.114 by -$0.036.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is 0.
How many shares outstanding does BeiGene have?
BeiGene has 97,717,560 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.114. Following the earnings report the stock price went down -5.56%.
Which hedge fund is a major shareholder of BeiGene?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$258.65 (14.00% Upside)
$258.65 (14.00% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 48.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.19%
12-Months-Change
Fundamentals
Return on Equity
-25.04%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
ONC Stock 12 Month Forecast
Average Price Target
$258.65
▲(14.00% Upside)
Technical Analysis
Best Analysts Covering ONC
1 Year
1 Year Success Rate
13/13 ratings generated profit
1 Year Average Return
+17.08%
reiterated a buy rating 7 days ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +17.08% per trade.
---